( PALO ALTO Calif. April 09 2007 /PRN...)Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting,Health

PALO ALTO, Calif., April 09, 2007 /PRNewswire-FirstCall/ -- Telik, Inc. announced that updated clinical data from its multicenter Phase 2 trial of the triplet combination of TELCYTA(R) (canfosfamide HCl, TLK286), carboplatin and paclitaxel will be presented at the 98th annual meeting of the American Association for Cancer Research (AACR) in Los Angeles. Preclinical studies of cellular and molecular correlates of synergistic cancer cell growth inhibition with TELCYTA in combination with standard chemotherapy, and studies describing TELCYTA's potential anti-angiogenic activity, also will be presented.

    Details of the presentations are as follows:


    -- Phase 2 Multicenter Dose-Ranging Trial of TLK286 (Canfosfamide HCl) in

       Combination with Carboplatin and Paclitaxel as First-Line Treatment for

       Advanced Non-Small Cell Lung Cancer; Tuesday, April 17, 2007,

       8:00 am - noon; Phase II-III Adult Clinical Trials; Abstract # 3521


    -- Cellular and Molecular Correlates of Synergistic Growth Inhibition in

       Human Lung Cancer Cells by TLK286 (Canfosfamide HCl), a Novel

       Glutathione Analog Prodrug, in Combination with Paclitaxel and

       Carboplatin; Sunday, April 15, 2007, 8:00 am - noon; Drug Delivery I;

       Abstract # 1502


    -- TLK286 (Canfosfamide HCl), a Novel Glutathione Analog Prodrug, Exhibits

       Antiangiogenic Effects Including the Inhibition of Human Endothelial

       Cell Proliferation and Capillary Tubule Formation In Vitro; Tuesday,

       April 17, 2007, 1:00 - 5:00 pm; Angiogenesis II: Novel Inhibitors;

       Abstract # 4622

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA, a tumor-activated small molecule product candidate in clinical develo
'"/>